Financials in USD. Standardized financial statements.
A compact view of how Fusion Pharmaceuticals Inc. turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|
| Revenue? | $2.07M | $1.46M | $1.44M | $0 | $0 | $0 | $0 |
| Revenue Growth? | +41.5% | +1.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $1.34M | $58.90M | $56.36M | $482,000 | $290,000 | $0 | $0 |
| Gross Profit? | $723,000 | -$57.43M | -$54.92M | -$482,000 | -$290,000 | $0 | $0 |
| Gross Margin? | +35.0% | -3931.1% | -3813.7% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $99.95M | $89.50M | $83.45M | $37.94M | $18.04M | $9.76M | $6.99M |
| Operating Income? | -$99.23M | -$88.03M | -$82.02M | -$37.94M | -$18.22M | -$10.10M | -$6.99M |
| EBITDA? | -$87.60M | -$87.26M | -$81.38M | -$31.05M | -$17.75M | -$9.65M | -$6.96M |
| Income Before Tax | -$94.11M | -$89.45M | -$81.17M | -$75.72M | -$15.94M | -$11.47M | -$6.26M |
| Income Tax Expense | $787,000 | -$1.84M | -$118,000 | $2.61M | $251,000 | $181,000 | $0 |
| Net Income? | -$94.90M | -$87.61M | -$81.05M | -$78.33M | -$16.19M | -$11.65M | -$6.26M |
| EPS? | $-1.45 | $-2.00 | $-1.90 | $-3.56 | $-0.10 | $-0.62 | $-0.34 |
| Diluted EPS? | $-1.45 | $-2.00 | $-1.90 | $-3.56 | $-0.10 | $-0.62 | $-0.34 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality